This could be explained by a finding that obese patients with MASLD have increased IFNα and decreased IFNγ levels, and IFNα but not IFNγ levels are associated with the accumulation of intramuscular fat, an important contributor to insulin resistance [59]. Here, IFNA2 is linked to metabolic dysfunction-associated steatotic liver disease.